Inhibrx Biosciences, Inc. has recently made headlines with an amended Schedule 13G filing, revealing that Bank of America Corp has increased its stake in the company to 2.4%. This development is significant as it reflects a growing interest in Inhibrx and the broader biological products sector, which is increasingly attracting attention from major financial institutions.

Background

Inhibrx Biosciences, Inc. operates in the biological products sector, specifically focusing on innovative therapies. The company is listed on the Nasdaq under the ticker INBX and is classified under the Standard Industrial Classification (SIC) code 2836, which pertains to biological products (no diagnostic substances). Recent filings include an amended Schedule 13G on October 28, 2026, and a Form 4 on October 14, 2026.

What the Filing Says

The filing indicates that Bank of America Corp now holds a total of 357,318 shares of Inhibrx, which accounts for 2.4% of the company’s outstanding shares. The beneficial ownership calculation is based on the 14,717,660 outstanding shares reported in Inhibrx's Form 10-Q filed on August 13, 2026. The filing states, "The beneficial ownership calculation relies on the 14,717,660 outstanding shares disclosed in the Form 10-Q by the issuer on August 13, 2026."

Impact

This increase in stake by Bank of America may impact various stakeholders, including investors, analysts, and competitors within the biological products industry. As financial institutions like Bank of America show confidence in Inhibrx, it may lead to increased scrutiny and interest from other investors and industry players. The filing does not specify any immediate actions or changes that will follow this stake increase.

What's Next

The filing does not say what happens next. However, the increased stake by Bank of America may lead to further developments in Inhibrx's strategic initiatives and partnerships in the future.